Post-trial follow-up | Longer-term all-cause and cardiovascular mortality with intensive blood pressure control.

Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control: A Secondary Analysis of a Randomized Clinical Trial – JAMA Cardiology (free for a limited period)

Author Interview: Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control – JAMA

Commentaries:

Benefits of Intensive Blood Pressure Control May Not Persist After Trial Intervention – HCP Live

Study Highlights Importance of Long-term Management of Hypertension – Wake Forest University School of Medicine

Related:

SPRINT Trial final report: targeting a systolic BP of less than 120 mm Hg in patients at increased CV risk is associated with improved CV and mortality outcomes but increases the risk of serious adverse events.

Study: Real-world blood pressure measurements vs. measurements taken in the SPRINT trial

Studies: Intensive versus Standard Blood-Pressure Control

Commentary on Twitter

In a secondary analysis of SPRINT, the mortality benefits of intensive BP control attenuated after the trial, while outpatient systolic BP increased by an average of 7 mm Hg for participants in the intensive treatment group. https://t.co/INSo2zYzhp #Research

— JAMA Cardiology (@JAMACardio) October 12, 2022